ANDAOPHTHALMICSUSPENSION/DROPS
Approved
Feb 2022
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
TOBRAMYCIN AND DEXAMETHASONE (tobramycin and dexamethasone) by Design Pharmaceuticals is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 2022.
Drug data last refreshed 18h ago
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis
Started Oct 2009
357 enrolled
ConjunctivitisKeratitisBlepharitis
Company
Worked on TOBRAMYCIN AND DEXAMETHASONE at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.